Currently, the predictive biomarkers commonly used in a clinical prognosis for RP include clinical phenotypes (including sex, age, smoking history, chemotherapy history, types of tumor pathology, and clinical stages), biological biomarkers (such as levels of IL-6, IL-8, TGF-β, and other cytokines in the serum), and radiophysical properties (including V5, V20, V10, V30, and mean lung dose). Here, IL6 is linked to neoplasm.